Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study to Determine the Safety, Maximum Tolerated Dose, PK of BAY43-9006 in Repeated Cycles of 18 Days On/3 Days Off in Combination With Paclitaxel and Carboplatin Chemotherapy in Patients With Advanced, Refractory Solid Tumors

NCT00941863 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT00941863
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00941863 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study to Determine the Safety, Maximum Tolerated Dose, PK of BAY43-9006 in Repeated Cycles of 18 Days On/3 Days Off in Combination With Paclitaxel and Carboplatin Chemotherapy in Patients With Advanced, Refractory Solid Tumors
Lead sponsor
Bayer
Phase
Phase 1
Overall status
Completed
Start date
July 31, 2002
Completion date
April 30, 2008
Enrollment
158 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma